A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS

BACKGROUND. Acute respiratory distress syndrome (ARDS) is a prevalent disease with significant mortality for which no effective pharmacologic therapy exists. Low-dose inhaled carbon monoxide (iCO) confers cytoprotection in preclinical models of sepsis and ARDS. METHODS. We conducted a phase I dose e...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JCI Insight
Main Authors: Fredenburgh, Laura E., Perrella, Mark A., Barragan-Bradford, Diana, Hess, Dean R., Peters, Elizabeth, Welty-Wolf, Karen E., Kraft, Bryan D., Harris, R. Scott, Maurer, Rie, Nakahira, Kiichi, Oromendia, Clara, Davies, John D., Higuera, Angelica, Schiffer, Kristen T., Englert, Joshua A., Dieffenbach, Paul B., Berlin, David A., Lagambina, Susan, Bouthot, Mark, Sullivan, Andrew I., Nuccio, Paul F., Kone, Mamary T., Malik, Mona J., Porras, Maria Angelica Pabon, Finkelsztein, Eli, Winkler, Tilo, Hurwitz, Shelley, Serhan, Charles N., Piantadosi, Claude A., Baron, Rebecca M., Thompson, B. Taylor, Choi, Augustine M.K.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Clinical Investigation 2018
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6328240/
https://ncbi.nlm.nih.gov/pubmed/30518685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.124039
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים